{"DataElement":{"publicId":"3597293","version":"1","preferredName":"Hematopoietic Cell Transplant Relapse Risk Category","preferredDefinition":"Classification to signify the likelihood of recurrence of malignancy following hematopoietic cell transplantation, based on one or more of the following parameters: marrow morphology, flow cytometry, cytogenetic studies, including fluorescence in situ hybridization, electrophoresis, immunofixation assays, and polymerase chain reaction-based assays for disease  markers, or imaging results.","longName":"HCT_REL_RSK_CAT","context":"CCR","contextVersion":"1","DataElementConcept":{"publicId":"3597287","version":"1","preferredName":"Hematopoietic Cell Transplant Relapse Risk","preferredDefinition":"Recurrence of malignancy following hematopoietic cell transplantation, based on one or more of the following parameters: marrow morphology, flow cytometry, cytogenetic studies, including fluorescence in situ hybridization, electrophoresis, immunofixation assays, and polymerase chain reaction-based assays for disease  markers, or imaging results._Risk is the potential future harm that may arise from some present action. It is often combined or confused with the probability of an event which is seen as undesirable. (from WIkipedia)","longName":"HCT_REL_RSK","context":"CCR","contextVersion":"1","ObjectClass":{"publicId":"3597285","version":"1","preferredName":"Hematopoietic Cell Transplant Relapse","preferredDefinition":"Recurrence of malignancy following hematopoietic cell transplantation, based on one or more of the following parameters: marrow morphology, flow cytometry, cytogenetic studies, including fluorescence in situ hybridization, electrophoresis, immunofixation assays, and polymerase chain reaction-based assays for disease  markers, or imaging results.  ","longName":"C103152","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hematopoietic Cell Transplant Relapse","conceptCode":"C103152","definition":"Recurrence of malignancy following hematopoietic cell transplantation, based on one or more of the following parameters: marrow morphology, flow cytometry, cytogenetic studies, including fluorescence in situ hybridization, electrophoresis, immunofixation assays, and polymerase chain reaction-based assays for disease markers, or imaging results.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"CA98DD63-6955-EAF0-E040-BB89AD4350E8","latestVersionIndicator":"Yes","beginDate":"2012-09-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-09-26","modifiedBy":"ONEDATA","dateModified":"2012-09-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2829786","version":"1","preferredName":"Risk","preferredDefinition":"Risk is the potential future harm that may arise from some present action. It is often combined or confused with the probability of an event which is seen as undesirable. (from WIkipedia)","longName":"C17102","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Risk","conceptCode":"C17102","definition":"The potential future harm that may arise from some present action. It is often combined or confused with the probability of an event which is seen as undesirable.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"616FA566-B7E8-2870-E040-BB89AD434025","latestVersionIndicator":"Yes","beginDate":"2009-01-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-01-26","modifiedBy":"ONEDATA","dateModified":"2009-01-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008563","version":"1","preferredName":"Therapy Results","preferredDefinition":"the results or effects (does not include CTC Adverse Events) of therapeutic agents or procedures administered to the patient.","longName":"TX_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B6690D31-4081-494A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-01-06","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-02-11","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CA98DD63-6963-EAF0-E040-BB89AD4350E8","latestVersionIndicator":"Yes","beginDate":"2012-09-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-09-26","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3597289","version":"1","preferredName":"Hematopoietic Cell Transplant Relapse Risk Category","preferredDefinition":"Recurrence of malignancy following hematopoietic cell transplantation, based on one or more of the following parameters: marrow morphology, flow cytometry, cytogenetic studies, including fluorescence in situ hybridization, electrophoresis, immunofixation assays, and polymerase chain reaction-based assays for disease  markers, or imaging results._Risk is the potential future harm that may arise from some present action. It is often combined or confused with the probability of an event which is seen as undesirable. (from WIkipedia)_Category; used informally to mean a class of things.","longName":"HCT_REL_RSK_CAT","context":"CCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"14","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Standard Risk","valueDescription":"Hematopoietic Cell Transplant Relapse Standard Risk Rate","ValueMeaning":{"publicId":"3597290","version":"1","preferredName":"Hematopoietic Cell Transplant Relapse Standard Risk Rate","longName":"3597290","preferredDefinition":"Risk of hematopoietic cell transplant relapse rates per patient year with p value between 0.26 and 0.37.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hematopoietic Cell Transplant Relapse Standard Risk Rate","conceptCode":"C103154","definition":"Risk of hematopoietic cell transplant relapse rates per patient year with p value between 0.26 and 0.37.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CA98DD63-699E-EAF0-E040-BB89AD4350E8","latestVersionIndicator":"Yes","beginDate":"2012-09-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-09-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CA98DD63-69B7-EAF0-E040-BB89AD4350E8","beginDate":"2012-09-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-09-26","modifiedBy":"ONEDATA","dateModified":"2012-09-26","deletedIndicator":"No"},{"value":"Low Risk","valueDescription":"Hematopoietic Cell Transplant Relapse Low Risk Rate","ValueMeaning":{"publicId":"3597291","version":"1","preferredName":"Hematopoietic Cell Transplant Relapse Low Risk Rate","longName":"3597291","preferredDefinition":"Risk of hematopoietic cell transplant relapse rates per patient year with p value between 0.00 and 0.24.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hematopoietic Cell Transplant Relapse Low Risk Rate","conceptCode":"C103153","definition":"Risk of hematopoietic cell transplant relapse rates per patient year with p value between 0.00 and 0.24.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CA98DD63-69C3-EAF0-E040-BB89AD4350E8","latestVersionIndicator":"Yes","beginDate":"2012-09-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-09-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CA98DD63-69DC-EAF0-E040-BB89AD4350E8","beginDate":"2012-09-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-09-26","modifiedBy":"ONEDATA","dateModified":"2012-09-26","deletedIndicator":"No"},{"value":"High Risk","valueDescription":"Hematopoietic Cell Transplant Relapse High Risk Rate","ValueMeaning":{"publicId":"3597292","version":"1","preferredName":"Hematopoietic Cell Transplant Relapse High Risk Rate","longName":"3597292","preferredDefinition":"Risk of hematopoietic cell transplant relapse rates per patient year with p value higher than 0.52.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hematopoietic Cell Transplant Relapse High Risk Rate","conceptCode":"C103155","definition":"Risk of hematopoietic cell transplant relapse rates per patient year with p value higher than 0.52.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CA98DD63-69E8-EAF0-E040-BB89AD4350E8","latestVersionIndicator":"Yes","beginDate":"2012-09-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-09-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CA98DD63-6A01-EAF0-E040-BB89AD4350E8","beginDate":"2012-09-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-09-26","modifiedBy":"ONEDATA","dateModified":"2012-09-26","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008563","version":"1","preferredName":"Therapy Results","preferredDefinition":"the results or effects (does not include CTC Adverse Events) of therapeutic agents or procedures administered to the patient.","longName":"TX_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B6690D31-4081-494A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-01-06","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-02-11","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3597288","version":"1","preferredName":"Hematopoietic Cell Transplant Relapse Risk Category","preferredDefinition":"Recurrence of malignancy following hematopoietic cell transplantation, based on one or more of the following parameters: marrow morphology, flow cytometry, cytogenetic studies, including fluorescence in situ hybridization, electrophoresis, immunofixation assays, and polymerase chain reaction-based assays for disease  markers, or imaging results.  :Risk is the potential future harm that may arise from some present action. It is often combined or confused with the probability of an event which is seen as undesirable. (from WIkipedia):Category; used informally to mean a class of things.","longName":"C103152:C17102:C25372","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hematopoietic Cell Transplant Relapse","conceptCode":"C103152","definition":"Recurrence of malignancy following hematopoietic cell transplantation, based on one or more of the following parameters: marrow morphology, flow cytometry, cytogenetic studies, including fluorescence in situ hybridization, electrophoresis, immunofixation assays, and polymerase chain reaction-based assays for disease markers, or imaging results.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Risk","conceptCode":"C17102","definition":"The potential future harm that may arise from some present action. It is often combined or confused with the probability of an event which is seen as undesirable.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Category","conceptCode":"C25372","definition":"A grouping of items based on some commonality or by user defined characteristics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CA98DD63-6978-EAF0-E040-BB89AD4350E8","latestVersionIndicator":"Yes","beginDate":"2012-09-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-09-26","modifiedBy":"ONEDATA","dateModified":"2012-09-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CA98DD63-6989-EAF0-E040-BB89AD4350E8","latestVersionIndicator":"Yes","beginDate":"2012-09-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-09-26","modifiedBy":"ONEDATA","dateModified":"2012-09-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811685","version":"1","longName":"CCR","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Relapse Risk","type":"Preferred Question Text","description":"Relapse Risk","url":null,"context":"CCR"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CA98DD63-6A0B-EAF0-E040-BB89AD4350E8","latestVersionIndicator":"Yes","beginDate":"2012-09-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-09-26","modifiedBy":"REEVESD","dateModified":"2012-09-26","changeDescription":"Curated to support NCI CCR transplant trial","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}